Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

NCT00191633 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

DRUG: Atomoxetine

Sponsor

Eli Lilly and Company